Klotho Neurosciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KLTO research report →
Price Chart
About the company
Klotho Neurosciences, Inc. operates as a biopharmaceutical enterprise focused on devising medical treatments for various conditions, including cancer, cardiovascular ailments, and neurodegenerative disorders. Their leading gene therapy assets encompass AMI-101, which is designed for the management or prevention of Alzheimer's disease, and AMI-202, aimed at treating or averting amyotrophic lateral sclerosis.
- CEO
- Joseph A. Sinkule
- IPO
- 2022
- Employees
- 3
- HQ
- Omaha, NE, US
Get TickerSpark's AI analysis on KLTO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $20.08M
- P/E
- -0.52
- PEG
- -0.01
- P/S
- 0.00
- P/B
- 0.28
- EV/EBITDA
- -0.43
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -67.62%
- ROIC
- -29.13%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-7,146,265
- Net Income
- $-10,551,674-71.6%
- EPS
- $-0.22+31.3%
- OCF Growth
- -98.8%
- FCF Growth
- -90.8%
- 52W High
- $3.91
- 52W Low
- $0.11
- 50D MA
- $0.34
- 200D MA
- $0.63
- Beta
- 2.23
- RSI (14)
- 56
- Avg Volume
- 3.23M
No earnings-call transcripts are available for KLTO yet.
- Free Float
- 76.4%
- Shares Outstanding
- 52.70M
- Float Shares
- 40.26M
of shares held by institutions
25 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 716.55K | ▲ 128.21K |
| Clear Street LLC | 90 | ▲ 90 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 4, 26 | LeBlanc Jeff | other | 2,500,000 |
| Mar 4, 26 | El-Dada Riad Hussein | other | 350,000 |
| Mar 4, 26 | ZENTMAN SAMUEL M | other | 350,000 |
| Mar 4, 26 | Hirschman Shalom | other | 350,000 |
| Mar 4, 26 | McGarity Jon | other | 350,000 |
| Mar 4, 26 | SINKULE JOSEPH | other | 2,500,000 |
| Dec 10, 25 | McGarity Jon | other | 20,000 |
| Dec 10, 25 | ZENTMAN SAMUEL M | other | 20,000 |
| Dec 10, 25 | El-Dada Riad Hussein | other | 20,000 |
| Sep 25, 25 | SINKULE JOSEPH | other | 400,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our KLTO coverage
Recent articles, reports, and earnings notes.
No research on KLTO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate KLTO report →Klotho Neurosciences (NASDAQ:KLTO) and Xenetic Biosciences (NASDAQ:XBIO) Head to Head Contrast
defenseworld.net · Apr 14
Citius Pharmaceuticals (NASDAQ:CTXR) and Klotho Neurosciences (NASDAQ:KLTO) Head-To-Head Comparison
defenseworld.net · Mar 28
Klotho Neurosciences Completes Rebranding to Greenland Mines Ltd and Change of Nasdaq Ticker Symbol to GRML
prnewswire.com · Mar 12
Klotho Neurosciences Announces Rebranding to Greenland Mines Ltd and Change of Nasdaq Ticker Symbol to GRML Effective March 12, 2026
prnewswire.com · Mar 9
KLOTHO NEUROSCIENCES ACQUIRES GREENLAND MINES CORP., SECURING CONTROL OF A $68 BILLION PALLADIUM, GOLD, PLATINUM, AND CRITICAL MINERAL DEPOSIT IN THE WORLD'S MOST STRATEGICALLY VITAL EMERGING TRADE CORRIDOR
prnewswire.com · Mar 4
Klotho Neurosciences (NASDAQ:KLTO) Initiates Development of the "Klotho Clock," a Diagnostic Biological Aging and Longevity Clock that Unlocks Health Testing Through Epigenetics and Artificial Intelligence (AI)
prnewswire.com · Feb 24
Klotho Neurosciences Receives Patent Claims in Australia for Composition and Use of Human Secreted Klotho Protein ("s-KL") Isoform of the Human Klotho Gene Sequence
prnewswire.com · Feb 18
Klotho Neurosciences to Present at the Biotech Showcase 2026
prnewswire.com · Jan 8
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.